Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

In preliminary Phase 1b/2a results released in January, the highest dose of the once-weekly injection led to 22% weight loss measured at 36 weeks. Last month, Metsera raised $275 million from its ...

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is expanding its presence in the weight loss and metabolic disease sector through a strategic collaboration with Metsera, Inc., announced in October 2024.

While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...

MET-097i is an ultra-long-acting GLP-1 receptor agonist that was shown in a phase 1/2 trial to achieve 7.5% weight loss over 36 days and a 380-hour (nearly 16-day) half-life, which Metsera said ...

Metsera’s lead injectable GLP-1 drug has already demonstrated significant weight loss and tolerability in a Phase 2 obesity trial. Cantor Fitzgerald’s analysis suggests that this drug could ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

Metsera, Inc. (NASDAQ ... the potential to address various therapeutic targets and meet the needs of the weight loss treatment industry. It was founded in 2022 by Population Health Partners ...

Metsera is engaged in the development of injectable and oral nutrient-stimulated hormone analog peptides to treat obesity and metabolic diseases. The New York City-headquartered company is working on ...